A Cost-Utility Analysis of SQ ® Tree SLIT-Tablet versus Placebo in the Treatment of Birch Pollen Allergic Rhinitis from a Swedish Societal Perspective.

Richard F PollockAndreas K SlættanesHenrik Brandi Tobias Sydendal Grand

Published in: ClinicoEconomics and outcomes research : CEOR (2023)

SQ Tree SLIT-Tablet improved quality of life in moderate-to-severe AR and/or conjunctivitis induced by pollen from the birch homologous group in Sweden, with only a modest increase in societal costs over a medium-term time horizon, representing good value for money at a willingness-to-pay threshold of SEK 700,000 per QALY.

Keyphrases

allergic rhinitis
dna damage
early onset
high intensity
health insurance
combination therapy
drug induced